- Cellular Origins, CGT Catapult, and Resolution Therapeutics have received a £1 million Innovate UK grant to deliver a fully automated, scalable CGT manufacturing platform.
- The 20-month project began on 1 July 2025, with the installation of Cellular Origins’ Constellation system at CGT Catapult’s Stevenage site.
Cellular Origins, a TTP company specialising in robotic manufacturing for cell and gene therapies (CGTs), has joined forces with CGT Catapult and Resolution Therapeutics to launch a new consortium project backed by a £1 million Smart Grant from Innovate UK. The goal is to develop what the partners describe as a “globally-unique” automated and scalable CGT manufacturing platform.
The 20-month initiative commenced on 1 July 2025. It aims to address a critical limitation in CGT production, where manual methods have restricted the industry’s capacity to reach more than 7% of eligible patients worldwide. The project will integrate the hardware and software of Constellation, Cellular Origins’ robotic platform, within the Digital and Automation Testbeds at CGT Catapult’s Stevenage Manufacturing Innovation Centre.
“This partnership with the CGT Catapult and Resolution Therapeutics, and the funding by Innovate UK, will deliver the most advanced, fully tested, fully automated robotically operated CGT manufacturing platform to the market,” said Edwin Stone, CEO of Cellular Origins.
The Testbeds provide a GMP-mirroring environment that allows accelerated adoption of new technologies. CGT Catapult will commission the system for real-world manufacturing to support national and international deployment. Additional technology support comes from ScaleReady and Autolomous, providing bioreactor and electronic batch record platforms, respectively.
Resolution Therapeutics, which is developing regenerative macrophage therapies, will contribute clinical and commercial insight to ensure the system is adaptable for next-generation therapies. The company’s lead asset, RTX001, is in Phase 1/2 trials for end-stage liver disease, with further indications in development.
The project underscores the growing role of robotics, AI, and automation in overcoming manufacturing bottlenecks in CGT, a critical challenge in expanding global patient access.
